LDS/Medical Tests/Chromosomal Microarray, Congenital, Blood

Chromosomal Microarray, Congenital, Blood

Chromosomal abnormalities are a common cause of congenital anomalies, developmental delay, and intellectual disability in neonates and children. These abnormalities may be numerical, such as aneuploidy, hypodiploidy, hyperdiploidy, or polyploidy, or structural, including deletions, duplications, amplifications, insertions, inversions, and unbalanced translocations. Traditional cytogenetic methods such as G-banded karyotyping can detect large chromosomal alterations; however, many clinically significant submicroscopic copy number variants (CNVs) fall below the resolution of conventional techniques.

Chromosomal microarray analysis (CMA) is a high-resolution, genome-wide assay that interrogates hundreds of thousands to millions of loci across the human genome using oligonucleotide and/or single nucleotide polymorphism (SNP) probes. CMA provides significantly higher resolution than standard karyotyping and is now recommended as a first-tier cytogenetic test for individuals with unexplained developmental delay, intellectual disability, autism spectrum disorder, or multiple congenital anomalies. The use of CMA has increased diagnostic yield from approximately 3% with conventional karyotyping to 10–25%, depending on the clinical indication.

This assay detects both inherited and de novo CNVs, including pathogenic deletions and duplications, and can identify regions of absence of heterozygosity that may suggest uniparental disomy, consanguinity, or imprinting disorders. CMA can also help clarify ambiguous karyotype findings and uncover clinically relevant genomic imbalances that inform diagnosis, prognosis, and medical management. Results from CMA support genetic counseling by providing information on recurrence risk and may guide further targeted testing or surveillance. In some cases, findings may be reported as variants of uncertain significance (VUS), which require correlation with clinical features and, when appropriate, parental studies or additional molecular testing.

  • First-line diagnostic test for children with unexplained developmental delay, intellectual disability, autism spectrum disorder, or multiple congenital anomalies
  • Identification of pathogenic copy number variants to support diagnosis, prognosis, and clinical management
  • Aids in genetic counseling and assessment of familial recurrence risk

Positive: Clinically significant chromosomal abnormalities were detected, including pathogenic or likely pathogenic copy number variants. Findings should be interpreted in the context of the patient’s clinical presentation and family history.

Negative: No clinically significant chromosomal abnormalities were detected. A normal result excludes most disorders caused by large chromosomal imbalances but does not rule out single-gene disorders, balanced rearrangements, low-level mosaicism, or sequence-level variants. Additional testing may be recommended based on clinical suspicion.

Normal cytogenetic profile

Chromosomal microarray analysis (CMA).

Whole blood, green-top (Heparin) or lavender-top (EDTA), 2mL. Alternative specimen: Cord blood.

Stability

  • Ambient: 3-5 days
  • Refrigerate: 5-7 days
Targeted gene panel or exome sequencing by NGS.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login